KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Receivables (2016 - 2025)

Evolent Health (EVH) has 11 years of Receivables data on record, last reported at $408.1 million in Q3 2025.

  • For Q3 2025, Receivables fell 0.61% year-over-year to $408.1 million; the TTM value through Sep 2025 reached $408.1 million, down 0.61%, while the annual FY2024 figure was $420.9 million, 99.91% down from the prior year.
  • Receivables reached $408.1 million in Q3 2025 per EVH's latest filing, up from $359.8 million in the prior quarter.
  • Across five years, Receivables topped out at $446.2 million in Q4 2023 and bottomed at $127.7 million in Q2 2022.
  • Average Receivables over 5 years is $308.7 million, with a median of $359.8 million recorded in 2025.
  • Peak YoY movement for Receivables: crashed 46.8% in 2022, then skyrocketed 186.77% in 2023.
  • A 5-year view of Receivables shows it stood at $171.5 million in 2021, then soared by 56.91% to $269.1 million in 2022, then soared by 65.82% to $446.2 million in 2023, then dropped by 5.67% to $420.9 million in 2024, then fell by 3.06% to $408.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $408.1 million in Q3 2025, $359.8 million in Q2 2025, and $429.2 million in Q1 2025.